Synthesis, characterization and in vitro anti-tumoral evaluation of Erlotinib-PCEC nanoparticles

Asian Pac J Cancer Prev. 2014;15(23):10281-7. doi: 10.7314/apjcp.2014.15.23.10281.

Abstract

Background: Development of a nanosized polymeric delivery system for erlotinib was the main objective of this research.

Materials and methods: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC) copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblock copolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by means of synthesized copolymers with solvent displacement method.

Results: Physicochemical properties of obtained polymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased with decreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulations was declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibited a sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release rate from polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers. Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72 hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8 μM.

Conclusions: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in this study might have the potential to be considered as delivery system for erlotinib.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Ethylene Oxide / chemical synthesis*
  • Humans
  • In Vitro Techniques
  • Lactones / chemical synthesis*
  • Nanoparticles*
  • Protein Kinase Inhibitors / pharmacology*
  • Proton Magnetic Resonance Spectroscopy
  • Quinazolines / pharmacology*
  • Spectroscopy, Fourier Transform Infrared

Substances

  • Lactones
  • PLC(20)-b-PEO(44)
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Ethylene Oxide